## Abstract We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino Xβlinked dystonia with parkinsonism, painful legs and moving toe
A therapeutic trial of milacemide in myoclonus and the stiff-person syndrome
β Scribed by P. Brown; P. D. Thompson; J. C. Rothwell; B. L. Day; Prof. C. D. Marsden
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 269 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
We investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred in the 10 patients.
π SIMILAR VOLUMES
A patient with osteosclerotic myeloma and POEMS syndrome, unresponsive to pulse prednisone and melphalan therapy, was admitted to the hospital for a trial of plasma exchange therapy. The presentation included IgG lambda monoclonal gammopathy, peripheral neuropathy. hepatosplenomegaly, hyperpigmentat
The majority of motor parasomnias and almost all nocturnal seizures occur out of NREM sleep. 1,2 The only well-defined disorders that are exclusively REM related are REM sleep behavior disorder (RBD) 3 and painful nocturnal erections. Catathrenia is a disorder that arises mostly but not exclusively
## Abstract In a Chinese myoclonusβdystonia syndrome (MDS) family presented with a phenotype including a typical MDS, cervical dystonia, and writer's cramp, genetic analyses revealed a novel 662 + 1insG heterozygous mutation in exon 5 in the Ξ΅βsarcoglycan (__SGCE__) gene, leading to a frameshift wi